OverviewSuggest Edit

Vor Biopharma is a biopharmaceutical company developing novel therapies for treating cancer. It develops a health and safety commission technology platform to address the limitations of the immunotherapies, including antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T cells. The company engineers hematopoietic stem cells (eHSCs) to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion.

TypePublic
Founded2016
HQCambridge, MA, US
Websitevorbio.com

Latest Updates

Employees (est.) (Jan 2021)76
Job Openings11
Share Price (Oct 2021)$15.9
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Vor Biopharma

Robert Ang

Robert Ang

Chief Executive Officer and Director
Sadik Kassim

Sadik Kassim

Chief Technology Officer
Tirtha Chakraborty

Tirtha Chakraborty

Chief Scientific Officer
Amy Mendel

Amy Mendel

Chief Legal Officer
John King

John King

Chief Commercial Officer
Christopher Slapak

Christopher Slapak

Chief Medical Officer
Show more

Vor Biopharma Office Locations

Vor Biopharma has an office in Cambridge
Cambridge, MA, US (HQ)
215 First St Suite 430
Show all (1)

Vor Biopharma Financials and Metrics

Vor Biopharma Revenue

USD

Net income (Q1, 2021)

(13.7m)

EBIT (Q1, 2021)

(13.7m)

Market capitalization (21-Oct-2021)

588.7m

Closing stock price (21-Oct-2021)

15.9

Cash (31-Mar-2021)

262.6m

EV

344.5m
Vor Biopharma's current market capitalization is $588.7 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

427.0k4.2m

R&D expense

2.4m6.2m

Operating expense total

2.9m10.4m

EBIT

(2.9m)(10.4m)
Quarterly
USDQ1, 2021

General and administrative expense

4.8m

R&D expense

8.9m

Operating expense total

13.7m

EBIT

(13.7m)
Annual
USDFY, 2018FY, 2019

Cash

929.0k6.5m

Prepaid Expenses

7.0k868.0k

Current Assets

936.0k7.5m

PP&E

71.0k728.0k
Quarterly
USDQ3, 2020Q1, 2021

Cash

63.6m262.6m

Prepaid Expenses

1.7m3.6m

Current Assets

65.5m266.3m

PP&E

3.6m5.7m
Annual
USDFY, 2018FY, 2019

Net Income

(4.2m)(10.8m)

Depreciation and Amortization

20.0k91.0k

Accounts Payable

65.0k1.2m

Cash From Operating Activities

(2.7m)(9.9m)
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

(6.9m)(27.7m)(13.7m)

Depreciation and Amortization

50.0k363.0k311.0k

Accounts Payable

2.7m3.7m(2.4m)

Cash From Operating Activities

(4.2m)(22.7m)(17.6m)
USDFY, 2018

Debt/Equity

-0.7 x

Debt/Assets

4.9 x

Financial Leverage

-0.1 x
Show all financial metrics

Vor Biopharma Operating Metrics

FY, 2020

Patents Pending

41
Show all operating metrics

Vor Biopharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Vor Biopharma Securities Corporation

Vor Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Vor Biopharma Online and Social Media Presence

Embed Graph

Vor Biopharma News and Updates

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with …

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in combination with targeted therapies for the treatment of cancer, today announced Matthew R. Patterson …

Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert Ang, MBBS, MBA, Vor’s P…

Vor Biopharma to Present at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barcla…

Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously announced initial publi…

Vor Biopharma prices upsized IPO at the top of the expected range, raises $177 million

Vor Biopharma Inc. , the Massachusetts-based cell therapy company focused on cancer treatments, said Friday that its upsized initial public offering priced at the top of the expected range to raise $176.9 million. The company, which was co-founded by PureTech Health PLC , said it sold 9.83 million s…
Show more

Vor Biopharma Blogs

Vor Announces FDA Clearance of IND Application for VOR33

Phase 1/2a clinical trial expected to begin in first half of 2021 CAMBRIDGE, Mass. – January 14, 2021 – Vor Biopharma, a clinical-stage cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced th…

Vor Biopharma Promotes Tirtha Chakraborty to Chief Scientific Officer

CAMBRIDGE, Mass. – November 19, 2020 – Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) combined with targeted therapies for the treatment of cancer, today announced the promotion of Tirtha Chakraborty, PhD, to Chief Scientific Officer. Dr. Chakraborty brings…

Vor Biopharma Announces Exclusive License of Clinical-Stage CD33 CAR-T from National Cancer Institute

CAMBRIDGE, Mass. – November 11, 2020 – Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced an exclusive licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), fo…

Vor Biopharma Appoints Matthew R. Patterson to its Board of Directors

CAMBRIDGE, Mass. – October 20, 2020 – Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Matthew R. Patterson, a biotechnology executive with nearly 30 years of experience in research, development,…

Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies

CAMBRIDGE, Mass., — September 29, 2020 — Vor Biopharma, an oncology company pioneering engineered hematopoietic stem cells (eHSCs) for the treatment of cancer, and Arbor Biotechnologies, an early-stage life sciences company, today announced an agreement to use Arbor’s gene editing technologies to en…

Vor Biopharma Frequently Asked Questions

  • When was Vor Biopharma founded?

    Vor Biopharma was founded in 2016.

  • Who are Vor Biopharma key executives?

    Vor Biopharma's key executives are Robert Ang, Sadik Kassim and Tirtha Chakraborty.

  • How many employees does Vor Biopharma have?

    Vor Biopharma has 76 employees.

  • Who are Vor Biopharma competitors?

    Competitors of Vor Biopharma include TScan Therapeutics, Elicio Therapeutics and Shoreline Biosciences.

  • Where is Vor Biopharma headquarters?

    Vor Biopharma headquarters is located at 215 First St Suite 430, Cambridge.

  • Where are Vor Biopharma offices?

    Vor Biopharma has an office in Cambridge.

  • How many offices does Vor Biopharma have?

    Vor Biopharma has 1 office.